😊 In a Phase I trial, CT-388 showed a median weight loss of 18.8% compared to placebo, with 70% achieving over 15% weight loss.
🔬 Roche plans to evaluate CT-388 in obese patients with type 2 diabetes in a separate trial.
💪 With obesity affecting one billion people worldwide, this drug could be a promising solution for weight loss.
Introduction:
Roche’s obesity candidate CT-388, acquired through the acquisition of Carmot Therapeutics, has shown promising results in a Phase I trial. The trial demonstrated that CT-388 can lead to significant weight loss and normalize blood glucose levels in patients. Obesity is a major health challenge worldwide, and drugs like CT-388 that target weight loss and glucose reduction could offer new treatment options.
- CT-388, a Phase Ib GLP-1/GIP agonist, led to a median weight loss of 18.8% compared to placebo in a Phase I trial.
- 100% of patients lost more than 5% of their weight, and 70% achieved more than 15% weight loss.
- CT-388 showed a characteristic side effect profile and normalized blood glucose levels in prediabetic patients.
- Obesity is a major health challenge with life-threatening comorbidities, and CT-388 could offer a new treatment approach.
- Further trials will evaluate CT-388 in obese patients with type 2 diabetes, with data expected in the second half of 2024.
Conclusion:
The Phase I trial results for Roche’s obesity candidate CT-388 are encouraging, showing significant weight loss and blood glucose normalization. These findings offer hope for new treatment options in the fight against obesity and its associated health risks. Further trials will provide more insights into the efficacy and safety of CT-388 in obese patients with type 2 diabetes.
